.png)
Professor Bruce Robinson was appointed as a Non-Executive Director effective 2 February 2026.
Professor Robinson is a renowned physician, academic, and advisor with over 25 years’ experience as a leader in healthcare. In addition to being a highly experienced practising endocrinologist, Professor Robinson currently serves as a Non-Executive Director of major listed healthcare entities Cochlear Limited (ASX:COH) (since 13 December 2016) and Mayne Pharma Group Limited (ASX:MYX) (since 26 August 2014). He is also a Non-Executive Director of British speciality pharmaceutical company CS Pharmaceuticals Ltd (since 24 October 2024) and an advisor to Minter Ellison.
Professor Robinson’s former roles include Chair of the Australian Government’s taskforce of expert clinicians charged with reviewing the Medicare Benefits Schedule, the Medical Benefits Schedule Review Taskforce, and chair of Australia’s peak advisory and funding body for medical research, the National Health and Medical Research Council. He is a former Dean of the University of Sydney’s Medical School, the former head of the Cancer Genetics Unit at the Kolling Institute, Royal North Shore Hospital, and the former Head, Division of Medicine, Royal North Shore Hospital.
Professor Robinson was awarded a Doctor of Medicine from the University of Sydney in 1990, having earlier undertaken a fellowship at Harvard Medical School and graduated from the University of Sydney with a Master of Science degree. Professor Robinson is a Fellow of the Australian Institute of Company Directors.